JAK Inhibition in Ulcerative Colitis

Leiden University Medical Center (LUMC)

Status: Enrolling

Conditions: Colitis, Ulcerative

Treatments: Other: JAK inhibitor treatment

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05456412

81808

Details and patient eligibility

About

The treatment for Ulcerative Colitis (UC) aims to achieve and maintain remission and is usually lifelong and expensive. Current available medications are unable to break the cycle of chronic inflammation, and still a significant proportion of patients will fail to respond (primary non-response) or lose response over time (secondary non-response). There is now growing evidence that there is substantial interpatient variation in the composition of the inflammation associated network of immune cells. A deeper knowledge of the patient's alterations in the mucosal immune response would help identify key drivers of inflammation and select the appropriate therapy. By analyzing the changes in the composition of immune cells induced by Janus Kinase (JAK) inhibition, we aim to obtain a better insight into the mechanistic effects of JAK inhibition and the downstream effects. These mechanistic insights are needed to identifying potential responders and non-responders in the future.

Enrollment: 60 estimated patients

Sex: All

Ages: 16 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Age Ulcerative colitis active disease

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Sequential Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

Treatment JAK inhibitor

Experimental group

Description:

Clinical practice is followed for all patients treated with JAK inhibitor. Additional biopsies and blood is taken.

Treatment:

Other: JAK inhibitor treatment